Q1 EPS Estimate for Voyager Therapeutics Lifted by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at HC Wainwright lifted their Q1 2026 EPS estimates for Voyager Therapeutics in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.28) for the quarter, up from their previous estimate of ($0.30). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at ($0.91) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The company had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million.

Separately, Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics has an average rating of “Hold” and a consensus target price of $16.50.

Voyager Therapeutics Trading Down 4.1%

Voyager Therapeutics stock opened at $3.76 on Thursday. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55. The firm’s fifty day simple moving average is $3.92 and its 200-day simple moving average is $4.19. The company has a market capitalization of $224.10 million, a P/E ratio of -1.85 and a beta of 1.32.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wexford Capital LP bought a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $42,000. ProShare Advisors LLC acquired a new position in Voyager Therapeutics in the 4th quarter valued at $44,000. CIBC Asset Management Inc bought a new position in Voyager Therapeutics in the 4th quarter worth $45,000. Bank of Montreal Can bought a new position in Voyager Therapeutics in the 2nd quarter worth $36,000. Finally, Coldstream Capital Management Inc. acquired a new position in Voyager Therapeutics during the 3rd quarter worth $55,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer owned 484,060 shares in the company, valued at $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 49,783 shares of company stock worth $188,694 over the last three months. 6.39% of the stock is owned by corporate insiders.

More Voyager Therapeutics News

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a large $25 price target (roughly 565% above current levels), which is a clear bullish signal that can attract buyers and lift the stock. Benzinga: HC Wainwright Reiterates Buy
• Positive Sentiment: Analyst P. Trucchio raised near-term 2026 quarterly forecasts (Q1–Q4 2026 and FY2026) — e.g., FY2026 EPS was revised from ($1.18) to ($1.09) and several quarters were nudged less negative — implying a slightly improved short-term outlook that can support a rally. AmericanBankingNews: HC Wainwright Note
• Neutral Sentiment: HC Wainwright also published updated quarterly estimates for 2027 (Q1–Q4 2027) and reiterated multi-year modeling; these scheduled estimate updates add transparency but are largely model detail rather than new fundamental catalysts. AmericanBankingNews: FY2027 Estimates
• Negative Sentiment: Offsetting the near-term upgrades, HC Wainwright lowered several longer-term EPS forecasts (FY2027–FY2030 were revised more negative — e.g., FY2027 from ($1.17) to ($1.34), FY2028 from ($1.49) to ($1.60), FY2030 from ($0.83) to ($0.91)). That signals weaker long-term profitability expectations and raises risk for longer-horizon investors. AmericanBankingNews: Long-term Estimate Cuts

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.